Ipilumumab Plus Pembrolizumab Vs Pembrolizumab Alone In PdL1 More Than 50 Percentage Which Is Better

12 Mar, 2021

Dr. Rajesh Bollam

Image
#Lungcancer
#is more always better ?
Ipilumumab plus pembrolizumab vs pembrolizumab alone in pdL1 more than 50 percentage
Which is better
Single agent pembrolizumab is better
The addition of IPI in #lungCancer failed AGAIN to improve survival combined w/ another ICI (here Pembro)
🔻NO OS & PFS benefit (HR>1)
🔻High % of irAEs (20.2 vs 7.8%)
Mono ICI remains t standard in PDL1≥50%
📑full JCO just out👇🏻

Add a comment